Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments

Technology appraisal guidance
Reference number: TA947
Published: 31 January 2024

History

Expected publication

Register of interests (PDF 291 KB)

Published:

31 January 2024

Final draft guidance

Final draft guidance
Final draft guidance (PDF 258 KB)

Published:

14 December 2023
Committee papers (PDF 811 KB)

Published:

14 December 2023
Public committee slides (PDF 674 KB)

Published:

14 December 2023
Final draft guidance - Equality impact assessment (PDF 157 KB)

Published:

14 December 2023

Draft guidance

Draft guidance
Draft guidance (PDF version) (PDF 280 KB)

Published:

03 October 2023
Draft guidance (online commenting)
Committee papers (PDF 8.64 MB)

Published:

03 October 2023
Public committee slides (PDF 785 KB)

Published:

03 October 2023

Invitation to participate

Final scope (PDF 211 KB)

Published:

13 January 2023
Final stakeholder list (PDF 172 KB)

Published:

13 January 2023
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 219 KB)

Published:

13 January 2023
Equality impact assessment (Scoping) (PDF 122 KB)

Published:

13 January 2023

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft matrix post referral (PDF 167 KB)

Published:

21 October 2022
Draft scope post referral (PDF 214 KB)

Published:

21 October 2022